Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Title:
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Author:
Roberts, John D. Shibata, Stephen Spicer, Darcy V. McLeod, Howard L. Tombes, Mary Beth Kyle, Brenda Carroll, Mary Sheedy, Beth Collier, Mary A. Pithavala, Yazdi K. Paradiso, Linda J. Clendeninn, Neil J.